Related references
Note: Only part of the references are listed.TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis
Austin G. Kulasekararaj et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia
Daniel A. Pollyea et al.
HAEMATOLOGICA (2013)
A phase 1 study of concomitant high-dose lenalidomide and 5-azacitidine induction in the treatment of AML
G. Ramsingh et al.
LEUKEMIA (2013)
Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis
A. Kuendgen et al.
LEUKEMIA (2013)
Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes
Mikkael A. Sekeres et al.
BLOOD (2012)
Aberrant methylation of the M-type phospholipase A2 receptor gene in leukemic cells
Mario Menschikowski et al.
BMC CANCER (2012)
Impact of lenalidomide on the functional properties of human mesenchymal stromal cells
Manja Wobus et al.
EXPERIMENTAL HEMATOLOGY (2012)
Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial
Katja Sockel et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Hagop M. Kantarjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Topography, Clinical, and Genomic Correlates of 5q Myeloid Malignancies Revisited
Andres Jerez et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Interest of the association azacitidine-lenalidomide as frontline therapy in high-risk myelodysplasia or acute myeloid leukemia with complex karyotype
E. Scherman et al.
LEUKEMIA (2012)
Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia
D. A. Pollyea et al.
LEUKEMIA (2012)
Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study
Haifa K. Al-Ali et al.
LEUKEMIA & LYMPHOMA (2012)
Clinical Results With the DNA Hypomethylating Agent 5-Aza-2′-Deoxycytidine (Decitabine) in Patients With Myelodysplastic Syndromes: An Update
Tina E. Joeckel et al.
SEMINARS IN HEMATOLOGY (2012)
Allogeneic Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndromes
Uwe Platzbecker
SEMINARS IN HEMATOLOGY (2012)
Lenalidomide for del(5q) and Non-del(5q) Myelodysplastic Syndromes
Aristoteles A. N. Giagounidis
SEMINARS IN HEMATOLOGY (2012)
Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes
Mikkael A. Sekeres et al.
AMERICAN JOURNAL OF HEMATOLOGY (2011)
A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia
Todd A. Fehniger et al.
BLOOD (2011)
Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine
Raphael Itzykson et al.
BLOOD (2011)
Lenalidomide in AML: Del(5q) or who?
David P. Steensma et al.
BLOOD (2011)
A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605
Mikkael A. Sekeres et al.
BLOOD (2011)
Dexamethasone and lenalidomide have distinct functional effects on erythropoiesis
Anupama Narla et al.
BLOOD (2011)
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q
Pierre Fenaux et al.
BLOOD (2011)
Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities
Lars Mollgard et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Unraveling the Molecular Pathophysiology of Myelodysplastic Syndromes
Rafael Bejar et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate-or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group
Michael Luebbert et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression
Martin Jaedersten et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
Rafael Bejar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid
Andrea Kuendgen et al.
CLINICAL EPIGENETICS (2011)
CR with lenalidomide in del(5)(q13q33) AML relapsing after allogeneic hematopoietic SCT
C. D. Ford et al.
BONE MARROW TRANSPLANTATION (2010)
Efficacy of lenalidomide in an sAML patient with del 5q relapsing after reduced-intensity allogeneic stem cell transplantation performed in complete remission
L. Ades et al.
BONE MARROW TRANSPLANTATION (2010)
Azacitidine for the Treatment of Lower Risk Myelodysplastic Syndromes
Pellegrino Musto et al.
CANCER (2010)
Phase I Combination Trial of Lenalidomide and Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes
Mikkael A. Sekeres et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Persistent Malignant Stem Cells in del(5q) Myelodysplasia in Remission
Ramin Tehranchi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13
Todd A. Fehniger et al.
BLOOD (2009)
Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study
Lionel Ades et al.
BLOOD (2009)
Aberrant DNA methylation is a dominant mechanism in MDS progression to AML
Ying Jiang et al.
BLOOD (2009)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells
C. Flotho et al.
LEUKEMIA (2009)
A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide
Sheng Wei et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Relationship of Treatment-Related Cytopenias and Response to Lenalidomide in Patients With Lower-Risk Myelodysplastic Syndromes
Mikkael A. Sekeres et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype
C. Haferlach et al.
LEUKEMIA (2008)
Identification of RPS14 as a 5q- syndrome gene by RNA interference screen
Benjamin L. Ebert et al.
NATURE (2008)
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1-risk myelodysplastic syndromes with karyotypes other than deletion 5q
Azra Raza et al.
BLOOD (2008)
Lenalidomide as induction therapy before allogeneic stem cell transplantation in a patient with proliferative CMML-2 and del(5q) not involving the EGR1 locus
Gustav Carus
LEUKEMIA (2007)
Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q-syndrome patients
Andrea Pellagatti et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Lenalidomide in the context of complex karyotype or interrupted treatment:: case reviews of del(5q) MDS patients with unexpected responses
Aristoteles A. N. Giagounidis et al.
ANNALS OF HEMATOLOGY (2007)
Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells
Dominique Verhelle et al.
CANCER RESEARCH (2007)
Treatment of deletion 5q acute myeloid leukemia with lenalidomide
J. E. Lancet et al.
LEUKEMIA (2007)
The pathogenesis of myelodysplastic syndromes (MDS)
Uwe Platzbecker et al.
CANCER TREATMENT REVIEWS (2007)
Treatment of acute myelogenous leukemia with outpatient azacitidine
Nimit Sudan et al.
CANCER (2006)
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion
Alan List et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup
AAN Giagounidis et al.
ANNALS OF HEMATOLOGY (2005)
Approval summary: Azacitidine for treatment of myelodysplastic syndrome subtypes
E Kaminskas et al.
CLINICAL CANCER RESEARCH (2005)
Efficacy of lenalidomide in myelodysplastic syndromes
A List et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro
K Dredge et al.
MICROVASCULAR RESEARCH (2005)
Epigenetics in human disease and prospects for epigenetic therapy
G Egger et al.
NATURE (2004)
Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs
PH Schafer et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment
M Daskalakis et al.
BLOOD (2002)
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B
LR Silverman et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Share Paper
